Sign in
CompletedNo phase

Prognostic Impact of Admission Glucose Level in Septic Patients Admitted to the Intensive Care Unit

Key facts

Who runs it
Meir Medical Center
Where
Israel1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
224 people enrolled
Started
1 Dec 2023
Ended
1 Feb 2024
Type of study
Observational, 2 groups
Treatments tested
  • No intervention- observational study
Record updated
15 March 2024

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • -

Who cannot take part

  • -

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Sepsis is one of the most common reasons for admission to intensive care units (ICU) worldwide. About 30% of all patients admitted to intensive care suffer from sepsis (1). Sepsis causes an extreme physiological stress response, with significant changes in metabolism and disruption in glucose regulation. Disorder of glucose regulation can lead to hyperglycemia, hypoglycemia and glucose variability (2). All of these conditions are associated with increased mortality (3). In critically-ill patients, the glucose threshold from which damage may be caused remains controversial.

Hyperglycemia often occurs in critically-ill patients suffering from sepsis, even in those who were not diabetic before, for several reasons. Sepsis causes massive activation of anti-inflammatory mediators which enhances the activity of counter-regulatory hormones, including cortisol, glucagon and catecholamines. Those hormones increase both hepatic gluconeogenesis and peripheral resistance to insulin (4). Some of the detrimental effects of hyperglycemia in septic patients are mediated via hyperglycemia-induced blood hypercoagulable state, decrease of vascular endothelial responsiveness and disrupted process of phagocytosis and chemotaxis of white blood cells, especially neutrophils (5).

It is widely accepted that disordered blood glucose regulation increases mortality and morbidity, as well as hospital admission times and associated financial expenses (2,6). Blood glucose level at ICU admission was found to be a poor prognostic factor at various studies on different ICU patient populations (7-9). For example, in ICU patients admitted due to acute myocardial infarction, cardiogenic shock and need for urgent cardiac catheterization, high blood glucose levels at admission, even in non-diabetic patients, were associated with both increased in- hospital and long-term mortality (7). Among patients admitted due to acute heart failure, high admission glucose levels (above 200 mg / dL), in both diabetic and non-diabetic patients, were associated with higher mortality from cardio-vascular etiologies within one year of admission (8). Among non-diabetic patients admitted to the hospital due to acute myocardial infarction, admission glucose levels above 180 mg / dL were associated with a significant increase in all-causes in-hospital mortality (9). However, there is currently insufficient information regarding the prognostic impact of high admission glucose levels of non-diabetic septic patients admitted to the ICU (10).

The 2 groups in the trial

  • Group A- Normal ICU admission blood glucose level

    Patients with admission blood glucose level lower than 180 mg / dL (but higher than 70 mg / dL).

    Treatment: No intervention- observational study

  • Group B- High ICU admission blood glucose level

    Patients with admission blood glucose level higher than 180 mg / dL.

    Treatment: No intervention- observational study

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prognostic Impact of Admission Glucose Level in Septic Patients Admitted to the Intensive Care Unit- a Retrospective Study
Record updated
15 March 2024